+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating the best low-density lipoprotein LDL cholesterol targets for adults who have had a small vessel occlusion SVO stroke, a subtype of ischemic stroke. This trial addresses the lack of specific guidelines for LDL cholesterol levels tailored to different types of stroke, focusing on secondary prevention to reduce the risk of future cardiovascular events in patients with SVO stroke. The study is a multicenter, prospective, randomized, open, blinded-endpoint clinical trial led by Seoul National University Hospital. Participants will be randomly assigned to one of two groups aiming for different LDL cholesterol targets an intensive group targeting LDL cholesterol below 70 mgdL and a standard group targeting LDL cholesterol between 90 and 110 mgdL. Both groups will receive lipid-lowering medications including statins andor ezetimibe, and PCSK9 inhibitors may be used if LDL targets are not reached with initial therapies. The trial plans to enroll 4,016 adults with confirmed SVO stroke within 180 days before randomization. During the study, participants will be monitored for major adverse cardiovascular events such as cardiovascular death, stroke, and acute coronary syndrome over a follow-up period of at least four years. Researchers will assess various outcomes including any stroke, ischemic stroke or transient ischemic attack, myocardial infarction, and hemorrhagic stroke. Participants will undergo regular evaluations to measure LDL cholesterol levels and cardiovascular health, with safety and adherence closely monitored throughout the trial duration.

Age: 19Years +All GendersPhase Not Applicable
46 locations
R

Actively Recruiting

Researchers are evaluating the overall survival of patients with stage I epithelial ovarian cancer after they have undergone comprehensive staging surgery. This phase III trial compares the outcomes of adjuvant chemotherapy versus observation alone. The study aims to determine whether adding chemotherapy after surgery improves survival in this patient group. Participants will be randomly assigned to one of two groups. One group receives adjuvant chemotherapy, which includes either a combination of paclitaxel and carboplatin or docetaxel and carboplatin, given every three weeks for three to six cycles. Switching between paclitaxel and docetaxel is allowed if adverse events occur. The other group undergoes observation without chemotherapy. During the study, participants will be monitored for overall survival up to 60 months from randomization. Researchers will also assess relapse-free survival within the same timeframe. Evaluations include follow-ups to track disease progression, side effects, and general health. The study ensures participants receive appropriate care and measures outcomes to better understand treatment benefits and risks.

Age: 20Years +FEMALEPhase 3
103 locations
S

Actively Recruiting

This research focuses on adults in Korea who have chronic or episodic migraine, a neurological condition causing moderate to severe headaches often accompanied by nausea, vomiting, and sensitivity to light and sound. The study aims to evaluate the safety and effectiveness of atogepant, a medication approved for preventing migraines, when used in regular clinical settings. Participants will take atogepant oral tablets as prescribed by their doctors, following the approved local guidelines. The study involves approximately 3000 adults who will be observed during their routine medical care while using this medication. There are no additional treatments or burdens beyond what their physicians recommend. During the study, participants will attend their usual clinic or hospital visits up to 12 weeks. Researchers will monitor and record any adverse events, including serious or unexpected reactions, as well as common side effects. The main outcomes focus on safety measures related to atogepant use. The study will continue until May 2029, ensuring thorough observation of participants under typical care conditions.

Age: 19Years +All Genders
36 locations
P

Actively Recruiting

Researchers are evaluating ziftomenib, a drug targeting the menin pathway, for treating adults with acute myeloid leukemia AML who have specific genetic mutations. This research involves two parallel phase 3 studies comparing ziftomenib combined with standard therapies against placebo plus standard therapies in patients who have not yet received AML treatment. The studies focus on patients with nucleophosmin 1 mutation NPM1-m or lysine-specific methyltransferase 2A rearranged KMT2A-r AML. In the Nonintensive Therapy Study, older or medically unfit patients receive either ziftomenib or placebo alongside venetoclax and azacitidine. In the Intensive Therapy Study, medically fit patients are randomized to receive ziftomenib or placebo combined with cytarabine and daunorubicin during induction, cytarabine plus ziftomenib or placebo during consolidation, and ziftomenib or placebo alone during maintenance. Both studies use a double-blind design where neither patients nor physicians know the treatment assignments. Participants will be monitored for up to 36 months after enrollment, with evaluations including overall survival, event-free survival, complete remission rates, and measurable residual disease in bone marrow. Safety and tolerability will be assessed through adverse event reports and drug concentration measurements. Patient-reported outcomes related to health will also be collected. The total study duration extends up to November 2031, allowing long-term follow-up and assessment of treatment effects.

Age: 18Years +All GendersPhase 3
136 locations